CD24 and neoplasm: Beyond direct tumor targeting, Siglec blockade (e.g., anti-Siglec-7/-9/-10) can restore NK/T cell cytotoxicity [109,113,120], while interventions against tumor-associated sialoglycans (e.g., CD24-Siglec-10, GD3-Siglec-7) may enhance phagocytosis and NK activity [120,122].